Genetic therapies for spinal muscular atrophy type 1

The Lancet Neurology

Volumn 17, Issue 2, 2018, Pages 111-112

  Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; COMPLEMENTARY DNA; GENE THERAPY AGENT; NUSINERSEN; SURVIVAL MOTOR NEURON PROTEIN;

DRUG COST; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE THERAPY; HUMAN; MOTONEURON; NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; WERDNIG HOFFMANN DISEASE; HEREDITARY SPINAL MUSCULAR ATROPHY; SPINAL MUSCULAR ATROPHY;

GENETIC THERAPY; HUMANS; MUSCULAR ATROPHY, SPINAL; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD;

EID: 85037610436     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30436-2     Document Type: Note

References (7)

1. Mendell, JR, Al-Zaidy, S, Shell, R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377 (2017), 1713–1722.
2. Finkel, RS, Mercuri, E, Darras, BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377 (2017), 1723–1732.
3. Finkel, RS, McDermott, MP, Kaufmann, P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83 (2014), 810–817.
4. Hua, Y, Sahashi, K, Rigo, F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478 (2011), 123–126.
5. Aartsma-Rus, A, FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther 27 (2017), 67–69.
6. Simoens, S, Huys, I, Market access of Spinraza (nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations. Gene Ther 24 (2017), 539–541.
7. The Lancet Neurology. Treating rare disorders: time to act on unfair prices. Lancet Neurol, 16, 2017, 761.